Petros Pharmaceuticals, Inc. (PTPI)
| Market Cap | 83.49K |
| Revenue (ttm) | 5.11M |
| Net Income (ttm) | -29.66M |
| Shares Out | 2.14M |
| EPS (ttm) | -52.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,829,713 |
| Average Volume | 33,612,367 |
| Open | 0.0450 |
| Previous Close | 0.0474 |
| Day's Range | 0.0333 - 0.0564 |
| 52-Week Range | 0.0226 - 17.0000 |
| Beta | 2.20 |
| RSI | 26.79 |
| Earnings Date | May 22, 2025 |
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York. [Read more]
Full Company ProfileFinancial Performance
In 2024, Petros Pharmaceuticals's revenue was $5.11 million, a decrease of -12.20% compared to the previous year's $5.82 million. Losses were -$26.80 million, 94.0% more than in 2023.
Financial StatementsNews
Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
The Company Intends to Appeal the Delisting Determination NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on e...
Petros Pharmaceuticals partners with Innolitics to accelerate SaaS platform development
Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
With more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025 / ...
Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform
Company continues to innovate and develop its SaaS-based platform to facilitate Rx-to-OTC switch in line with recent President Trump Executive Order NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Petr...
Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches
Licensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again (M...
Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms
Company's AI and Big Data technology positioned to drive strong industry collaboration Company also announces certain corporate actions NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Petros Pharmac...
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the coun...
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceutic...
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-t...
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules
Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharma...
Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”
Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceutic...
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indications NEW YORK,...
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NAS...
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug developm...
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts t...
Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Vital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / July 16, 20...
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1] Ple...
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients (Please see important safety information below) NEW YORK, NY / ACCESSW...
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
(Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding con...
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% ...
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Sta...
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counter NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc....
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
FDA requests meeting to review the Company's technology component and discuss further development and requirements NEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:P...
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA® working to become the first erectile dysfunction m...
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
Human Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approval NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (...